compared to its rival Leqembi. However, experts caution against direct comparisons due to differences in patient groups ...

There was no difference between the two dosing regimens ... the rate of ARIA-E and ARIA-H are a little higher with Kisunla than with Leqembi. The company said it plans to submit the TRAILBLAZER ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

This option is one of the key differences between Kisunla and Leqembi, which was administered throughout its clinical trials. So at USC, doctors have a weekly meeting to discuss how patients are ...

Her husband isn't sure if it made a difference. In 2020, Sue Bell became one of the ... That sort of uncertainty is common when it comes to Leqembi and Kisunla, two new Alzheimer's drugs approved ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

The National Medical Products Administration (NMPA) has cleared Kisunla (donanemab ... significant difference. Lilly has said that its drug has advantages over Leqembi, including approval for ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

"But I'm not sure." That sort of uncertainty is common when it comes to Leqembi and Kisunla, two new Alzheimer's drugs approved since 2023. Both drugs clear the brain of a substance called beta ...

Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a negative coverage decision for Eli Lilly’s Kisunla came in October 2024. Following a request ...